Recent reports suggest that Quest Diagnostics (DGX) is gaining positive attention in the market. Named to Fortune's World's Most Admired Companies List for the 12th Consecutive Year, the firm has been commended not only for its reputation but also for its focus on at-home testing. A series of investment firms including Rakuten Investment Management and Boston Common Asset Management have invested significant amounts into Quest Diagnostics demonstrating investor confidence. The firm has also entered a joint venture with Corewell Health to bolster its laboratory analysis capacity in Michigan.
Concurrently, their financial performance indicates a promising trajectory with steady share price performance leading some to believe that it is undervalued. This, combined with better-than-expected Q3 Earnings, raised outlook, and the decision to increase the quarterly cash dividend, further amplifies this belief. They have actively worked towards improving their services through collaborations like that with Epic and Google Cloud aimed at enhancing customer experience and streamlining data management using generative AI. These ventures and active steps to evolve their service portfolio further position the firm as innovatively poised to further capitalize on the market's potentialities.
Quest Diagnostics DGX News Analytics from Tue, 18 Mar 2025 07:00:00 GMT to Sat, 24 Jan 2026 14:32:02 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -3
